Tedizolid (formerly torezolid) is an oxazolidinone drug being developed by Cubist Pharmaceuticals following acquisition of Trius Therapeutics (originator: Dong-A Pharmaceuticals) for complicated skin and skin-structure infections (cSSSI) including those caused by methicillin-resistant Staphylococcus aureus (MRSA).The prodrug tedizolid is called TR-701 while the active mioety is called TR-700.
This page contains content from the copyrighted Wikipedia article "Tedizolid"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
